Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (19694)	10/17/2006 8:23:24 PM
From: ACAN	Respond to of 23958

Ray; [PPHM] looks good to me Allan

To: Galirayo who wrote (19694)	10/17/2006 8:42:46 PM
From: J.F.	Respond to of 23958

PPHM - now there's an oldie but goodie. Haven't looked at that one in awhile. Used to be on my watch. The 144 & the 200 look good. I like it... Thank you sir... jf...

To: Galirayo who wrote (19694)	10/30/2006 8:57:27 AM
From: ACAN	Read Replies (3) \| Respond to of 23958

Ray; [PPHM} Positive Results From Peregrine's Bavituximab Phase Ia HCV Trial Presented At AASLD Meeting Monday October 30, 8:00 am ET -First-in-Class Targeted Immunotherapeutic Agent Appears Safe and Well Tolerated at All Doses Tested in Single Dose Trial in Patients With Chronic HCV infection- -Final Study Data Confirm Encouraging Signs of Anti-Viral Activity in Patients Who Had Failed Traditional Anti-Viral Therapies- - Enrollment in Phase Ib Repeat Dose HCV Trial Recently Completed and Planning for Additional Trials Underway- Allan